Positive Trigger
now
Phase 3 ENERGIZE study of 'Mitapivat' in thalassemia successfully achieves primary endpoint by slashing blood transfusion dependence by over 50%.
24h Trigger History
No history available
No trigger updates found for this ticker in the last 24 hours.
| Advertisement |